U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 10911 - 10920 of 13501 results

Status:
Investigational
Source:
INN:simufilam [INN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Status:
Investigational
Source:
INN:moxazocine
Source URL:

Class (Stereo):
CHEMICAL (MIXED)

Moxazocine is a benzomorphan derivative patented by Bristol-Myers Co. as potent opioid analgesic. Moxazocine acts as a partial agonist or mixed agonist/antagonist of the opioid receptors and binds preferentially to the κ-opioid receptor. In clinical studies, Moxazocine demonstrated superior efficacy compared morphine, but was never marketed.
Status:
Investigational
Source:
INN:darbinurad [INN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Status:
Investigational
Source:
NCT02590952: Phase 1 Interventional Completed Solid Tumor
(2011)
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Status:
Investigational
Source:
INN:odatroltide [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
NCT03428958: Phase 1/Phase 2 Interventional Completed Colorectal Cancer
(2018)
Source URL:

Class (Stereo):
CHEMICAL (EPIMERIC)

Status:
Investigational
Source:
INN:lanepitant
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

LANEPITANT is a selective nonpeptide antagonist for the neurokinin-1 receptor. It inhibits neurogenic dural inflammation. LANEPITANT was under development as a potential analgesic drug for the treatment of migraine, arthritis and diabetic neuropathy. However, it failed to show sufficient efficacy to support further development.
Status:
Investigational
Source:
NCT03228433: Phase 1 Interventional Completed Healthy Participants
(2017)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
INN:simufilam [INN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Status:
Investigational
Source:
NCT04594369: Phase 3 Interventional Completed Non-Cystic Fibrosis Bronchiectasis
(2020)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Showing 10911 - 10920 of 13501 results